Continual evolution of type 2 diabetes: An update on pathophysiology and emerging treatment options

Therapeutics and Clinical Risk Management

Volumn 11, Issue , 2015, Pages 621-632

  Cornell, Susan ^a  

^a MIDWESTERN UNIVERSITY   (United States)

Author keywords

Diabetes; Hyperglycemia; Oral antidiabetic therapies; Pharmacotherapy; Sodium glucose cotransporter 2

Indexed keywords

AGENTS AFFECTING CARBOHYDRATE METABOLISM; ANTIDIABETIC AGENT; CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; FASIGLIFAM; G PROTEIN COUPLED RECEPTOR 119 AGONIST; INCB 13739; IPRAGLIFLOZIN; JNJ 38431055; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; AGE; BRAIN; DIET; EXERCISE; GASTROINTESTINAL TRACT; GENETICS; GLUCOTOXICITY; GLYCEMIC CONTROL; HUMAN; KIDNEY; LIPOTOXICITY; LIVER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKELETAL MUSCLE; WEIGHT REDUCTION;

EID: 84928108305     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S67387     Document Type: Review

References (128)

1. International Diabetes Federation. 2013. IDF Atlas. Available from: http://www.idf.org/diabetesatlas. Accessed July 10, 2014.
2. Centers for Disease Control and Prevention. 2014. National diabetes statistics report: estimates of diabetes and its burden in the United States, 2014. Available from: http://www.cdc.gov/diabetes/pubs/statsreport14/ national-diabetes-report-web.pdf. Accessed July 16, 2014.
3. Rowley WR, Bezold C. Creating public awareness: state 2025 diabetes forecasts. Popul Health Manag. 2012;15:194–200.
4. DeFronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58:773–795.
5. Fonseca VA. Defning and characterizing the progression of type 2 diabetes. Diabetes Care. 2009;32:S151–S156.
6. Warram JH, Martin BC, Krolewski AS, Soeldner JS, Kahn CR. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Intern Med. 1990; 113:909–915.
7. Mills GW, Avery PJ, McCarthy MI, et al. Heritability estimates for beta cell function and features of the insulin resistance syndrome in UK families with an increased susceptibility to type 2 diabetes. Diabetologia. 2004;47:732–738.
8. Grant RW, Moore AF, Florez JC. Genetic architecture of type 2 diabetes: recent progress and clinical implications. Diabetes Care. 2009; 32:1107–1114.
9. Kahn SE. Clinical review 135: the importance of beta-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab. 2001;86:4047–4058.
10. Chang AM, Halter JB. Aging and insulin secretion. Am J Physiol Endocrinol Metab. 2003;284:E7–E12.
11. Hu FB. Globalization of diabetes: the role of diet, lifestyle, and genes. Diabetes Care. 2011;34:1249–1257.
12. Poitout V, Robertson RP. Minireview: secondary beta-cell failure in type 2 diabetes – a convergence of glucotoxicity and lipotoxicity. Endocrinology. 2002;143:339–342.
13. Carpentier A, Mittelman SD, Bergman RN, Giacca A, Lewis GF. Prolonged elevation of plasma free fatty acids impairs pancreatic beta-cell function in obese nondiabetic humans but not in individuals with type 2 diabetes. Diabetes. 2000;49:399–408.
14. Kashyap S, Belfort R, Gastaldelli A, et al. A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes. 2003;52: 2461–2474.
15. Unger RH, Zhou YT. Lipotoxicity of beta-cells in obesity and in other causes of fatty acid spillover. Diabetes. 2001;50:S118–S121.
16. Gerich JE, Meyer C, Woerle HJ, Stumvoll M. Renal gluconeogenesis: its importance in human glucose homeostasis. Diabetes Care. 2001;24:382–391.
17. Heit JA, Leibson CL, Ashrani AA, Petterson TM, Bailey KR, Melton LJ. Is diabetes mellitus an independent risk factor for venous throm-boembolism?: a population-based case-control study. Arterioscler Thromb Vasc Biol. 2009;29:1399–1405.
18. Shah P, Vella A, Basu A, Basu R, Schwenk WF, Rizza RA. Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2000;85:4053–4059.
19. Huang S, Czech MP. The GLUT4 glucose transporter. Cell Metab. 2007; 5:237–252.
20. Herman MA, Kahn BB. Glucose transport and sensing in the maintenance of glucose homeostasis and metabolic harmony. J Clin Invest. 2006;116: 1767–1775.
21. Cusi K, Maezono K, Osman A, et al. Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J Clin Invest. 2000;105:311–320.
22. Bays H, Mandarino L, DeFronzo RA. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab. 2004;89: 463–478.
23. Saely CH, Geiger K, Drexel H. Brown versus white adipose tissue: a mini-review. Gerontology. 2012;58:15–23.
24. Cypess AM, Lehman S, Williams G, et al. Identifcation and importance of brown adipose tissue in adult humans. N Engl J Med. 2009; 360:1509–1517.
25. Saito M, Okamatsu-Ogura Y, Matsushita M, et al. High incidence of metabolically active brown adipose tissue in healthy adult humans: effects of cold exposure and adiposity. Diabetes. 2009;58:1526–1531.
26. van Marken Lichtenbelt WD, Vanhommerig JW, Smulders NM, et al. Cold-activated brown adipose tissue in healthy men. N Engl J Med. 2009;360:1500–1508.
27. Virtanen KA, Lidell ME, Orava J, et al. Functional brown adipose tissue in healthy adults. N Engl J Med. 2009;360:1518–1525.
28. Ouellet V, Labbe SM, Blondin DP, et al. Brown adipose tissue oxidative metabolism contributes to energy expenditure during acute cold exposure in humans. J Clin Invest. 2012;122:545–552.
29. Bostrom P, Wu J, Jedrychowski MP, et al. A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012;481:463–468.
30. Pagotto U. Where does insulin resistance start? The brain. Diabetes Care. 2009;32:S174–S177.
31. Tschritter O, Preissl H, Hennige AM, et al. The cerebrocortical response to hyperinsulinemia is reduced in overweight humans: a magnetoencephalographic study. Proc Natl Acad Sci U S A. 2006;103: 12103–12108.
32. Roth JD, Maier H, Chen S, Roland BL. Implications of amylin receptor agonism: integrated neurohormonal mechanisms and therapeutic applications. Arch Neurol. 2009;66:306–310.
33. Woods SC, Lutz TA, Geary N, Langhans W. Pancreatic signals controlling food intake; insulin, glucagon and amylin. Philos Trans R Soc Lond B Biol Sci. 2006;361:1219–1235.
34. Friedman JM. Leptin at 14 y of age: an ongoing story. Am J Clin Nutr. 2009;89:973S–979S.
35. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med. 1996;334:292–295.
36. Morton GJ, Schwartz M W. Leptin and the central nervous system control of glucose metabolism. Physiol Rev. 2011;91:389–411.
37. Farooqi IS, O’Rahilly S. Leptin: a pivotal regulator of human energy homeostasis. Am J Clin Nutr. 2009;89:980S–984S.
38. German JP, Wisse BE, Thaler JP, et al. Leptin defciency causes insulin resistance induced by uncontrolled diabetes. Diabetes. 2010; 59:1626–1634.
39. Mittendorfer B, Horowitz JF, DePaoli AM, McCamish MA, Patterson BW, Klein S. Recombinant human leptin treatment does not improve insulin action in obese subjects with type 2 diabetes. Diabetes. 2011;60:1474–1477.
40. Heppner KM, Tong J. Mechanisms in endocrinology: regulation of glucose metabolism by the ghrelin system: multiple players and multiple actions. Eur J Endocrinol. 2014;171:R21–R32.
41. Date Y, Nakazato M, Hashiguchi S, et al. Ghrelin is present in pancreatic alpha-cells of humans and rats and stimulates insulin secretion. Diabetes. 2002;51:124–129.
42. Volante M, Allia E, Gugliotta P, et al. Expression of ghrelin and of the GH secretagogue receptor by pancreatic islet cells and related endocrine tumors. J Clin Endocrinol Metab. 2002;87:1300–1308.
43. Broglio F, Arvat E, Benso A, et al. Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. J Clin Endocrinol Metab. 2001;86:5083–5086.
44. Tong J, Prigeon RL, Davis HW, et al. Ghrelin suppresses glucose-stimulated insulin secretion and deteriorates glucose tolerance in healthy humans. Diabetes. 2010;59:2145–2151.
45. Garin MC, Burns CM, Kaul S, Cappola AR. Clinical review: the human experience with ghrelin administration. J Clin Endocrinol Metab. 2013; 98:1826–1837.
46. Pöykkö SM, Kellokoski E, Hörkkö S, Kauma H, Kesäniemi YA, Ukkola O. Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Diabetes. 2003;52:2546–2553.
47. Freeman JS. Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus. Cleve Clin J Med. 2009;76:S12–S19.
48. Nauck MA, Baller B, Meier JJ. Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes. Diabetes. 2004;53:S190–S196.
49. Dungan K, Buse JB. Glucagon-like peptide 1–based therapies for type 2 diabetes: a focus on exenatide. Clin Diabetes. 2005;23:56–62.
50. Bakris GL, Fonseca VA, Sharma K, Wright EM. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int. 2009;75:1272–1277.
51. Ferrannini E. Sodium-glucose transporter-2 inhibition as an antidiabetic therapy. Nephrol Dial Transplant. 2010;25:2041–2043.
52. DeFronzo RA, Hompesch M, Kasichayanula S, et al. Characterization of renal glucose reabsorption in response to dapaglifozin in healthy subjects and subjects with type 2 diabetes. Diabetes Care. 2013;36:3169–3176.
53. Stumvoll M, Chintalapudi U, Perriello G, Welle S, Gutierrez O, Gerich J. Uptake and release of glucose by the human kidney. Postabsorptive rates and responses to epinephrine. J Clin Invest. 1995;96:2528–2533.
54. Meyer C, Stumvoll M, Nadkarni V, Dostou J, Mitrakou A, Gerich J. Abnormal renal and hepatic glucose metabolism in type 2 diabetes mellitus. J Clin Invest. 1998;102:619–624.
55. Fox CS, Coady S, Sorlie PD, et al. Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation. 2007;115:1544–1550.
56. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298:2038–2047.
57. Foley RN, Collins AJ. End-stage renal disease in the United States: an update from the United States Renal Data System. J Am Soc Nephrol. 2007;18:2644–2648.
58. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103–117.
59. [No authors listed]. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998a;352:854–865.
60. [No authors listed]. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998b;352:837–853.
61. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580–591.
62. American Diabetes Association. Approaches to glycemic treatment. Sec 7. In Standards of medical care in diabetes – 2015. Diabetes Care. 2015;38(Suppl 1):S41–S48.
63. Garber AJ, Abrahamson MJ, Barzilay JI, et al. American Association of Clinical Endocrinologists’ comprehensive diabetes management algorithm 2013 consensus statement – executive summary. Endocr Pract. 2013;19:536–557.
64. Nathan DM, Buse JB, Davidson MB, et al; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193–203.
65. Knowler WC, Barrett-Connor E, Fowler SE, et al; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002; 346:393–403.
66. Cheung BM, Ong KL, Cherny SS, Sham PC, Tso AW, Lam KS. Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am J Med. 2009;122:443–453.
67. Schmittdiel JA, Uratsu CS, Karter AJ, et al. Why don’t diabetes patients achieve recommended risk factor targets? Poor adherence versus lack of treatment intensifcation. J Gen Intern Med. 2008;23:588–594.
68. Vallon V, Platt KA, Cunard R, et al. SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol. 2011;22: 104–112.
69. List JF, Whaley JM. Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans. Kidney Int. 2011; 79:S20–S27.
70. Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med. 2010;27:136–142.
71. Bolinder J, Ljunggren O, Kullberg J, et al. Effects of dapaglifozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97:1020–1031.
72. Bailey CJ. SGLT2 inhibitors: glucuretic treatment for type 2 diabetes. Br J Diabetes Vasc Dis. 2010;10:193–199.
73. Abdul-Ghani MA, Norton L, Defronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev. 2011;32:515–531.
74. Chao EC, Henry RR. SGLT2 inhibition – a novel strategy for diabetes treatment. Nat Rev Drug Discov. 2010;9:551–559.
75. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapaglifozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2010;33:2217–2224.
76. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapaglifozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375:2223–2233.
77. Nauck MA, Del Prato S, Meier JJ, et al. Dapaglifozin versus glip-izide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011;34:2015–2022.
78. Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S. Effect of dapaglifozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2011;13:928–938.
79. Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of dapaglifozin, an SGLT2 inhibitor, on HbA1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care. 2012;35:1473–1478.
80. Jabbour S, Hardy E, Sugg JE, Parikh S. Dapaglifozin as add-on therapy to sitagliptin with or without metformin: a randomized, double-blind, placebo-controlled study. Diabetes. 2012;61:A275.
81. Wilding JPH, Woo V, Soler NG, et al; Dapaglifozin 006 Study Group. Long-term effcacy of dapaglifozin in patients with type 2 diabetes mellitus receiving high doses of insulin. Ann Intern Med. 2012b;156: 405–415.
82. Henry RR, Murray AV, Marmolejo MH, Hennicken D, Ptaszynska A, List JF. Dapaglifozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract. 2012;66:446–456.
83. Kohan DE, Fioretto P, Tang W, List JF. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapaglifozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014;85:962–971.
84. Farxiga® (dapagliflozin). 2014. Full Prescribing Information. Princeton, NJ, USA: Bristol-Myers Squibb, and Wilmington, DE, USA: AstraZeneca; 2014.
85. Wilding JP, Woo V, Rohwedder K, Sugg J, Parikh S; Dapaglifozin 006 Study Group. Dapaglifozin in patients with type 2 diabetes receiving high doses of insulin: effcacy and safety over two years. Diabetes Obes Metab. 2014;16:124–136.
86. Bailey CJ, Gross JL, Hennicken D, Iqbal N, Mansfeld TA, List JF. Dapaglifozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med. 2013;11:43.
87. Bolinder J, Ljunggren O, Johansson L, et al. Dapaglifozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab. 2014;16:159–169.
88. Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapa-glifozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013;15:853–862.
89. Ptaszynska A, Chalamandaris A, Sugg JE, Johnsson KM, Parikh S, List JL. Effect of dapaglifozin on renal function. Diabetes. 2012;61:A283.
90. Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF. Vulvovaginitis and balanitis in patients with diabetes treated with dapaglifozin. J Diabetes Complications. 2013b;27:479–484.
91. Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF. Urinary tract infections in patients with diabetes treated with dapaglifozin. J Diabetes Complications. 2013a;27:473–478.
92. Stenlof K, Cefalu WT, Kim KA, et al. Efficacy and safety of canaglifozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15:372–382.
93. Cefalu WT, Leiter LA, Yoon KH, et al. Effcacy and safety of canagli-fozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013; 382:941–950.
94. Wilding JP, Mathieu C, Vercruysse F, et al. Canaglifozin (CANA), a sodium glucose co-transporter 2 inhibitor, improves glycemic control and reduces body weight in subjects with type 2 diabetes (T2D) inadequately controlled with metformin (MET) and sulfonylurea (SU). Diabetes. 2012a;61:A262.
95. Schernthaner G, Gross JL, Rosenstock J, et al. Canaglifozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care. 2013;36:2508–2515.
96. Yale JF, Bakris G, Cariou B, et al. Effcacy and safety of canaglifozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013;15:463–473.
97. Rosenstock J, Polodori D, Zhao Y, et al. Canaglifozin, an inhibitor of sodium glucose co-transporter 2, improves glycaemic control, lowers body weight, and improves beta cell function in subjects with type 2 diabetes on background metformin. Diabetologia. 2010b;53:S351.
98. Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev. 2011;91:733–794.
99. Polidori D, Sha S, Mudaliar S, et al. Canaglifozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care. 2013;36:2154–2161.
100. US Food and Drug Administration. Endocrinologic and Metabolic Drugs Advisory Committee, January 10, 2013. Available from: http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm331504.htm. Accessed July 16, 2014.
101. Sinclair A, Bode B, Harris S, et al. Effcacy and safety of canagli-fozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. BMC Endocr Disord. 2014;14:37.
102. Invokana® (canaglifozin). Full Prescribing Information. Titusville, NJ, USA: Janssen Pharmaceuticals; 2013.
103. Ferrannini E, Seman L, Seewaldt-Becker E, Hantel S, Pinnetti S, Woerle HJ. A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empaglifozin in patients with type 2 diabetes. Diabetes Obes Metab. 2013a;15:721–728.
104. Rosenstock J, Seman LJ, Jelaska A, et al. Effcacy and safety of empaglifozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes Obes Metab. 2013;15:1154–1160.
105. Kovacs CS, Seshiah V, Swallow R, et al; EMPA-REG PIO™ trial investigators. Empaglifozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab. 2014;16:147–158.
106. Haring HU, Merker L, Seewaldt-Becker E, et al; EMPA-REG METSU Trial Investigators. Empaglifozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2013;36: 3396–3404.
107. Woerle HJ, Ferrannini E, Berk A, et al. Safety and efficacy of empaglifozin as monotherapy or add-on to metformin in a 78-week open-label extension study in patients with type 2 diabetes. Diabetes. 2012;61:LB13.
108. Fonseca VA, Ferrannini E, Wilding JP, et al. Active- and placebo-controlled dose-fnding study to assess the effcacy, safety, and tolerability of multiple doses of ipraglifozin in patients with type 2 diabetes mellitus. J Diabetes Complications. 2013;27:268–273.
109. Wilding JP, Ferrannini E, Fonseca VA, Wilpshaar W, Dhanjal P, Houzer A. Effcacy and safety of ipraglifozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-fnding study. Diabetes Obes Metab. 2013a;15:403–409.
110. Ferrannini E, Veltkamp SA, Smulders RA, Kadokura T. Renal glucose handling: impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes. Diabetes Care. 2013b;36:1260–1265.
111. Seino Y, Sasaki T, Fukatsu A, Samukawa Y, Sakai S, Watanabe T. Luseo-glifozin (TS-071), a selective SGLT2 inhibitor, improves glycemic control and lowers body weight in Japanese patients with type 2 diabetes mellitus. Diabetes. 2012;61:A266.
112. Kadowaki T, Ikeda S, Takano Y, et al. Tofoglifozin, a novel and selective SGLT2 inhibitor improves glycemic control and lowers body weight in patients with type 2 diabetes mellitus inadequately controlled on stable metformin or diet and excercise alone. Diabetes. 2012;61:A22.
113. Mandema J, Sweeney K, Terra S, Sahasrabudhe V. Model-based meta-analysis of the HbA1c lowering effect of PF-04971729, a sodium glucose co-transporter-2 inhibitor (SGLT2i), in comparison with other SGLT2i and anti-diabetic agents (ADA). Diabetes. 2012;61:A260.
114. Zambrowicz B, Freiman J, Brown PM, et al. LX4211, a dual SGLT1/ SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther. 2012;92:158–169.
115. Overton HA, Fyfe MC, Reynet C. GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity. Br J Pharmacol. 2008;153:S76–S81.
116. GlaxoSmithKline. A study in type 2 diabetics of single and multiple doses of orally administered GSK1292263 to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics. Available from: http://clinicaltrials.gov/ct2/show/NCT01119846?term=gsk12 92263&rank=1. Accessed July 16, 2014.
117. CymaBay Therapeutics, Inc. Study to evaluate the effcacy, safety, tolerability, and pharmacokinetics of MBX-2982 administered daily for 4 weeks as monotherapy in patients with type 2 diabetes. Available from: http://clinicaltrials.gov/ct2/show/NCT01035879?term=mbx298 2&rank=1. Accessed July 16, 2014.
118. Katz LB, Gambale JJ, Rothenberg PL, et al. Effects of JNJ-38431055, a novel GPR119 receptor agonist, in randomized, double-blind, placebo-controlled studies in subjects with type 2 diabetes. Diabetes Obes Metab. 2012;14:709–716.
119. Kebede MA, Alquier T, Latour MG, Poitout V. Lipid receptors and islet function: therapeutic implications? Diabetes Obes Metab. 2009;11:10–20.
120. Burant CF, Viswanathan P, Marcinak J, et al. TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2012;379: 1403–1411.
121. Cooper MS, Stewart PM. 11Beta-hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome, and infammation. J Clin Endocrinol Metab. 2009;94:4645–4654.
122. Rosenstock J, Banarer S, Fonseca VA, et al; INCB13739-202 Principal Investigators. The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy. Diabetes Care. 2010a;33:1516–1522.
123. Inzucchi SE, Bergenstal RM, Buse JB, et al; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2012;35:1364–1379.
124. Inzucchi SE, Bergenstal RM, Buse JB, et al; Management of hyperg-lycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140–149.
125. Blonde L. Current antihyperglycemic treatment strategies for patients with type 2 diabetes mellitus. Cleve Clin J Med. 2009;76 Suppl 5: S4–S11.
126. Zangeneh F, Kudva YC, Basu A. Insulin sensitizers. Mayo Clin Proc. 2003;78:471–479.
127. Welchol® (colesevelam HCl). Full Prescribing Information. Parsip-pany, NJ, USA: Daiichi Sankyo, Inc.; 2010.
128. Cycloset® (bromocriptine mesylate). Full Prescribing Information. Tiverton, RI: VeroScience, LLC; 2010.